Back to top
more

AMN Healthcare Services (AMN)

(Delayed Data from NYSE)

$41.01 USD

41.01
1,000,317

-1.41 (-3.32%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $40.94 -0.07 (-0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 31% (173 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Hold on to Cerner (CERN) Stock Now

by Zacks Equity Research

Cerner (CERN) continues to gain traction from its robust strategic deals. However, stiff competition remains a woe.

Cardinal Health (CAH) Unveils the First Surgical Incise Drape

by Zacks Equity Research

Cardinal Health's (CAH) introduction of the first surgical incise drape is likely to lower SSIs.

AMN vs. GDRX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

AMN vs. GDRX: Which Stock Is the Better Value Option?

Here's Why You Should Retain Abbott (ABT) Stock for Now

by Zacks Equity Research

Investors are optimistic about Abbott (ABT) backed by its progress in the diabetes business.

Walgreens (WBA), Village MD Plan to Expand Into New Hampshire

by Zacks Equity Research

Walgreens (WBA) and VillageMD are working together to make it easier for the communities to access high-quality, coordinated primary care and pharmacy services.

AMN Healthcare Services (AMN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, AMN Healthcare Services (AMN) closed at $106.13, marking a -1.18% move from the previous day.

Reasons to Hold on to Myriad Genetics (MYGN) Stock For Now

by Zacks Equity Research

Investors are optimistic about Myriad Genetics (MYGN), backed by growth in tumor profiling and GeneSight test volumes.

Here's Why You Should Hold on to Insulet (PODD) Stock For Now

by Zacks Equity Research

Investors are optimistic about Insulet's (PODD) robust uptake of the Omnipod system both in the U.S. and international markets.

Here's Why You Should Buy McKesson (MCK) Stock Right Now

by Zacks Equity Research

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Reasons to Add AMN Healthcare (AMN) Stock to Your Portfolio

by Zacks Equity Research

Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.

Is AMN Healthcare (AMN) a Great Growth Stock?

by Zacks Equity Research

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider AMN Healthcare (AMN).

Is it the Right Time to Add Mednax (MD) Stock to Your Kitty?

by Zacks Equity Research

Growing revenues, numerous acquisitions, diversified care network and adequate cash generation abilities are likely to continue driving Mednax (MD).

Here's Why You Should Hold on to DaVita (DVA) Stock Now

by Zacks Equity Research

DaVita (DVA) continues to gain traction from its strong international presence and solid DaVita Kidney Care business. However, integration risks are a woe.

Here's Why You Should Retain Baxter (BAX) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio.

Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio For Now

by Zacks Equity Research

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

PerkinElmer's (PKI) Latest Launch to Boost Food Analysis Suite

by Zacks Equity Research

PerkinElmer's (PKI) latest launch is likely to simplify the process of critical food analyses.

Here's Why You Should Retain Cardinal Health (CAH) Stock Now

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, contraction in gross margin is a woe.

DexCom (DXCM) to Boost Diabetes Management With New Approval

by Zacks Equity Research

DexCom's (DXCM) G7 CGM System receives CE Mark that can help people with diabetes in Europe, including pregnant women.

McKesson (MCK) Hits 52-Week High: What's Aiding the Stock?

by Zacks Equity Research

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

Baxter (BAX) to Enhance Its Portfolio With Latest Partnership

by Zacks Equity Research

Baxter's (BAX) latest strategic partnership with Digital Diagnostics is expected to expand its connected care diagnostics portfolio.

Here's Why You Should Hold NextGen (NXGN) Stock For Now

by Zacks Equity Research

NextGen (NXGN) continues to gain momentum on the back of solid demand for its solutions and strength in EHR. Intense competition is a headwind.

Dexcom (DXCM) G6 CGM System Gets Public Coverage From Ontario

by Zacks Equity Research

Dexcom's (DXCM) G6 CGM System can help people with type 1 diabetes over two years of age through the coverage announced by the Ontario government.

AMN Healthcare Services (AMN) Gains As Market Dips: What You Should Know

by Zacks Equity Research

AMN Healthcare Services (AMN) closed at $93.78 in the latest trading session, marking a +1.98% move from the prior day.

Here's Why You Should Hold Onto Neogen (NEOG) Stock for Now

by Zacks Equity Research

Investors are optimistic about Neogen's (NEOG) progress at the Food Safety and Animal Safety segments.

Here's Why You Should Retain Masimo (MASI) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Masimo (MASI) owing to its focus on patient monitoring.